Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 326

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial

Jing, Zhi-Cheng, Parikh, Keyur, Pulido, Tomas, Jerjes-Sanchez, Carlos, White, R. James, Allen, Roblee, Torbicki, Adam, Xu, Kai-Feng, Yehle, David, Laliberte, Kevin, Arneson, Carl, Rubin, Lewis J.·2013·Circulation

Abstract

Background—: Pulmonary arterial hypertension (PAH) is a progressive, fatal disease with no cure. Parenteral and inhaled prostacyclin analogue therapies are effective for the treatment of PAH, but complicated administration requirements can limit the use of these therapies in patients with less severe disease. This study was designed to evaluate the safety and efficacy of the oral prostacyclin analogue treprostinil diolamine as initial treatment for de novo PAH. Methods and Results—: Three hundred forty-nine patients (intent-to-treat population) not receiving endothelin receptor antagonist or phosphodiesterase type-5 inhibitor background therapy were randomized (treprostinil, n=233; placebo, n=116). The primary analysis population (modified intent-to-treat) included 228 patients (treprostinil, n=151; placebo, n=77) with access to 0.25-mg treprostinil tablets at randomization. The primary end point was change from baseline in 6-minute walk distance at week 12. Secondary end points included Borg dyspnea index, clinical worsening, and symptoms of PAH. The week 12 treatment effect for 6-minute walk distance (modified intent-to-treat population) was 23.0 m ( P =0.0125). For the intent-to-treat population, 6-minute walk distance improvements were observed at peak (26.0 m; P =0.0001) and trough (17.0 m; P =0.0025) plasma study drug concentrations. Other than an improvement in the combined 6-minute walk distance/Borg dyspnea score, there were no significant changes in secondary end points. Oral treprostinil therapy was generally well tolerated; the most common adverse events (intent-to-treat) were headache (69%), nausea (39%), diarrhea (37%), and pain in jaw (25%). Conclusions—: Oral treprostinil improves exercise capacity in PAH patients not receiving other treatment. Oral treprostinil could provide a convenient, first-line prostacyclin treatment option for PAH patients not requiring more intensive therapy. Clinical Trial Registration:—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00325403 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.112.124388

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 326

Metadata

Authors
Jing, Z.-C., Parikh, K., Pulido, T., Jerjes-Sanchez, C., White, R. J., Allen, R., Torbicki, A., Xu, K.-F., Yehle, D., Laliberte, K., Arneson, C., & Rubin, L. J.
Venue
Circulation
Published
2013-02-05
Volume
127
Issue
5
Pages
624-633
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2129282733
Cited by
326
References
24
FWCI
31.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial. https://app.cochat.ai/papers/10.1161/circulationaha.112.124388
The paper
Jing, Z.-C., Parikh, K., Pulido, T., Jerjes-Sanchez, C., White, R. J., Allen, R., Torbicki, A., Xu, K.-F., Yehle, D., Laliberte, K., Arneson, C., & Rubin, L. J. (2013). Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial. Circulation. https://doi.org/10.1161/circulationaha.112.124388

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.